



Autophagy and bone diseases

Marie-Charlotte Trojani, Sabine Santucci-Darmanin, Véronique Breuil, Georges Carle, Valérie Pierrefite-Carle

► To cite this version:

Marie-Charlotte Trojani, Sabine Santucci-Darmanin, Véronique Breuil, Georges Carle, Valérie Pierrefite-Carle. Autophagy and bone diseases. Joint Bone Spine, 2022, 89 (3), pp.105301. <10.1016/j.jbspin.2021.105301>. <hal-03439454>

HAL Id: hal-03439454

<https://hal.science/hal-03439454v1>

Submitted on 5 Jan 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons CC BY-NC 4.0 - Attribution - Non-commercial use - International License

Autophagy and bone diseases

Marie-Charlotte Trojani^{1,2}, Sabine Santucci-Darmanin¹, Véronique Breuil^{1,2}, Georges F. Carle¹, Valérie Pierrefite-Carle^{1,3*}

(1) UMR E-430 TIRO-MATOS CEA/DRF Institut Joliot, Faculté de médecine de Nice, Université Nice Côte d'Azur, Avenue de Valombrose, 06107 Nice CEDEX 2, France. (2) Service de Rhumatologie, CHU de Nice, Nice, France. (3) INSERM, Paris, France.

Corresponding author: Dr Valérie Pierrefite-Carle, UMR E-430 TIRO-MATOS CEA/DRF/BIAM Institut Joliot, Université Nice Côte d'Azur, Faculté de médecine, 28 Av. de Valombrose, 06107 Nice cedex 2. Adresse email: pierrefi@unice.fr.

Abstract

Autophagy is a ubiquitous cellular process, allowing the removal and recycling of damaged proteins and organelles. At the basal level, this process plays a role in quality control, thus participating in cellular homeostasis. Autophagy can also be induced by various stresses, such as nutrient deprivation or hypoxia, to allow the cell to survive until conditions improve. In recent years, the role of this process has been widely studied in many pathologies such as neurodegenerative diseases or cancers. In bone tissue, various studies have shown that autophagy is involved in the survival, differentiation and activity of osteoblasts, osteocytes and osteoclasts. The evolution of this knowledge has led to the identification of new molecular pathophysiological mechanisms in bone pathologies.

This review reports the current state of knowledge on the role of autophagy in 4 bone diseases: osteoporosis, which seems to be associated with a decrease in autophagy, osteopetrosis and Paget's disease where the course of the autophagic process is disturbed, and finally osteosarcoma where autophagy seems to play a protumoral role. A better understanding of the involvement of autophagy in these pathologies should eventually lead to the identification of new potential therapeutic targets.

Keywords : Autophagy - Bone – Paget's disease of bone - Osteoporosis - Osteopetrosis - Osteosarcoma

1. Autophagy

1.1 Autophagy mechanism

Macroautophagy, commonly referred to as autophagy, is a ubiquitous cellular mechanism for the removal and recycling of damaged proteins and organelles [1]. At the basal level, this mechanism plays a key role in cellular quality control and homeostasis. Autophagy can also be induced in response to various stresses such as nutrient deprivation, oxidative stress, or hypoxia, to allow cell survival. Finally, under certain conditions, excessive autophagy can lead to cell death [1]. From a molecular point of view, in the presence of nutrients, autophagy is negatively regulated by the mTOR (mammalian target of rapamycin) complex. When the cell is deprived of nutrients or in any other situation of cellular stress, mTOR is inactivated. This inactivation leads to the activation of Unc-51 like autophagy activating kinase (ULK1) and then to the recruitment of a multiprotein complex called PI3K class III complex, which induces autophagy [1]. The autophagic process begins in the cytoplasm, where, under the combined action of different autophagy-related genes (ATGs), a double membrane called phagophore is formed. This phagophore encircles the damaged proteins and organelles and then closes, forming a double-membrane vesicle called an autophagosome. During this process, a cytosolic protein called ATG8 or LC3-I is lipidated and inserted into the double membrane of the autophagosome as LC3-II. Thus LC3-II is considered a marker of autophagosomes. The cellular material to be degraded is sequestered in the autophagosome by the action of specific autophagy receptors including the SQSTM1/p62 (p62) protein, which is considered a substrate of autophagy [2]. Subsequently, the lysosome fuses with the autophagosome, forming an autolysosome. The action of the lysosomal V-ATPase then leads to acidification of the vesicle resulting in degradation and subsequent recycling of material (Figure 1). Autophagy is a dynamic process, in which autophagosomes are constantly formed and then degraded, and is therefore referred to as autophagic flux. Thus, a decrease in LC3-II expression combined with an increase in p62 expression generally reflects a decrease in autophagy. On the other hand, an increase in LC3-II may reflect either

an induction of autophagy or an inhibition of autophagosome maturation, due for example to a defect in lysosomal activity.

The aim of this review is to summarize the main results concerning the role of autophagy in bone tissue and bone pathologies.

1.2 Autophagy and bone tissue

The role of autophagy in bone tissue was still unknown ten years ago [2]. However, the observation that most of the bone-promoting molecules such as vitamin D, estradiol, or bisphosphonates were known as autophagy inducers, suggested an important function of this process for bone quality [3]. In the last decade, our understanding of the autophagy role in bone tissue has significantly increased. It has been shown that autophagy is involved in the survival and differentiation of osteoblasts (OB) and osteocytes (OST) [4], and that this process is required for bone mineralization [5]. With regard to osteoclasts (OC), autophagy is involved in their differentiation [6] and some autophagy proteins are required for bone resorption, notably through their involvement in the brush border establishment and in the secretory activity of OCs [7].

2. Autophagy role in bone pathologies

2.1 Osteoporosis

Osteoporosis (OP) is a diffuse skeletal pathology characterized by major bone fragility that affects one in 3 women after menopause and one in 6 men after 50 years of age [8]. Multiple molecular mechanisms are involved in postmenopausal OP, but two crucial factors for disease onset are the decrease in estrogen and the increase in oxidative stress [9, 10]. Interestingly, estrogen appears to induce autophagy in bone cells [11, 12] while oxidative stress is generated by autophagy deficiency. In addition, a pan-genomic link has been observed between autophagy genes, human height and OP, suggesting that autophagy is involved in this pathology [13, 14]. In addition, several studies also support a role for autophagy in OP: (i) OB and OST from aged mice exhibit a decreased autophagy [15, 16]; (ii) autophagy increases in OST after ovariectomy, likely counterbalancing estrogen loss and

oxidative stress [16, 17]; (iii) autophagy activation in OST through treatment with the mTOR inhibitor rapamycin reduces OP severity [18]; (iv) bone loss related with aging and estrogen deprivation is exacerbated by an autophagy deficiency in OB [16]. All these results show that autophagy induction in OB and OST can compensate the deleterious effects of estrogen drop in OP, suggesting that this pathway represents a promising target for this pathology.

A link between deficient hematopoietic autophagy and OP has recently been evidenced in humans [19]. Moreover, a drastic bone loss along with an imbalance in OST homeostasis was observed in mice after Atg7 autophagy gene inactivation in hematopoietic cells [19]. This phenotype was associated with the disappearance of H-vessels, connecting OST and hematopoietic cells. In summary, autophagy induction in hematopoietic cells or in OB/OST could represent a new path in OP treatment (Figure 2A).

Some molecules already commercially available are known to modulate autophagy. For example, everolimus, an immunosuppressant that induces autophagy by inhibiting mTOR, decreases bone loss in a postmenopausal osteoporosis model in mice [20]. In humans, coupling an autophagy inducer such as everolimus or resveratrol to a compound with bone tropism could be used to stimulate autophagy specifically in the bone microenvironment.

In corticoid-induced OP, in addition to the decrease in bone formation that is the main mechanism involved in the pathology, there is an increase in resorption related to a prolongation of OC life [21, 22]. Although a relationship between autophagy and glucocorticoid treatment has already been established [23], the underlying molecular mechanism has only very recently been identified, and involves the PI3K/Akt/mTOR autophagic signaling pathway in primary OCs [24]. Thus, both in vitro and in vivo, glucocorticoid-treated OCs display an increased autophagic activity, suggesting that this pathway could be therapeutic target for corticoid-induced OP.

2.2 Osteopetrosis

This heterogeneous genetically inherited bone pathology, also called “marble bone disease”, results from OC function alteration. Its severity ranges from mild to a lethal form such as infantile malignant osteopetrosis (IMO) also called autosomal recessive osteopetrosis. This last form of osteopetrosis is characterized by an increased bone mass due to the OC resorption defect. Without bone marrow transplantation, which remains the only treatment to date, this disease is lethal in children [25].

The TCIRG1 gene, encoding the $\alpha 3$ subunit of V-ATPase, displays the large majority of mutations described in IMO patients although some mutations are also found in the CLC-7 gene or OSTM1 [26, 27]. The resorption activity in OC is affected by these mutations through lysosomal dysfunction. Several autophagy proteins have been shown to participate in the relocalization of this organelle to the brush border where the resorption takes place [7]. Moreover, lysosomes also play a major role in the final step of autophagy, allowing degradation and recycling of autophagosome content. Thus, autophagy appears to play a complex role in this rare bone pathology.

A defect in autophagy, characterized by a reduced LC3-II expression and an increased in p62 protein level, has been observed in OC of the osteopetrotic oc/oc mouse, a mouse model of IMO, carrying a homozygous mutation in the TCIRG1 gene [28]. In addition, mice models carrying OSTM1 or CLC-7 mutations exhibit, on top of an osteoporotic phenotype, a rapid neurodegeneration with an increased LC3-II expression in neurons [29, 30], suggesting a disrupted autophagic flux.

Finally, the PLEKHM1 gene, which is implicated in an intermediate type of human osteopetrosis and in osteoclastic vesicular trafficking in the incisorless rat model [31, 32], plays also a role in the regulation of the endosomal/autophagic pathway through the binding to LC3 and Rab7/HOPS proteins [33, 34]. In summary, most of osteopetrosis gene mutations affecting OC endosomal and lysosomal trafficking, appear to be also associated with neuronal and OC autophagy regulation (Figure 2B).

2.3 Paget disease of bone

Disorganized bone formation as well as an elevated bone resorption are the characteristics of Paget's disease of bone (PDB). Although most patients affected by this chronic focal disease are asymptomatic, joint or neurological complications can be observed due to fissures, fractures, and bone deformities. An increase of bone remodeling is observed, associated with the presence of "hyperactive" giant OCs with many nuclei [35]. Inclusion bodies composed of aggregates of ubiquitinated or misfolded proteins are also present in Pagetic OCs [36]. It seems that environmental and genetic factors are involved in PDB onset. Mutations in the p62/SQSTM1 gene are observed in 40% of familial cases and 10% of sporadic cases. Besides its role as an autophagy receptor, p62 has a key function in NF- κ B signaling and apoptosis during osteoclastogenesis [37]. The ubiquitin-associated domain (UBA) of the p62 gene

is the main target of mutations [37] and a point mutation in this domain appears sufficient to trigger PDB-like pathology in mice in which OC exhibit an increased autophagy level [38]. Nevertheless, a study on OC derived from PDB patients suggests an autophagy flux inhibition combined with a build-up of undegraded autophagosomes [39], potentially explaining the presence of inclusion bodies. The study of Usategui-Martín et al. strengthens the previous results as transfection of a p62 gene carrying one of the PDB mutations identified in patients results in autophagosome maturation inhibition [40]. An inhibition of cell proliferation via the NFκ-B pathway was also associated with this mutation [40]. In summary, these experimental results suggest an autophagy deregulation in PDB, which is further supported by ATG gene polymorphisms association with this pathology [41] and the implication of optineurin (OPTN), another autophagy receptor, as a predisposing gene for this disease [42]. More recently, the OATL1 gene, implicated in autophagosome maturation [43], appears to be also involved in PDB [37]. Altogether, these various studies, associated with the role of autophagy/ATG proteins in OC differentiation and function, strongly support the hypothesis of autophagy involvement in PDB (Figure 2C).

2.4 Osteosarcoma

Osteosarcoma (OS) is a malignant bone tumor, primarily of osteoblastic origin, with a peak incidence in childhood and adolescence. The lungs are the most common site of metastasis and the 5-year survival of patients with metastases is approximately 20%. From a genetic perspective, OS has major genomic complexity. Among the tumor suppressor genes frequently inactivated in OS, some such as RB1, PTEN or TP53 regulate autophagy. In parallel, various oncogenes that can be activated in OS also regulate autophagy. These data suggest a deregulation of autophagy in OS [44].

A dual role of autophagy is observed in OS as in other tumor types. OS tumor cells use autophagy as a survival pathway for treatment resistance, proliferation and cancer stem cell protection [44]. Thus, it seems interesting to specifically block autophagy in these cells, in order to potentiate the efficacy of classical therapies. For this purpose, we dispose of autophagy inhibiting molecules, such as hydroxychloroquine (late inhibitor) or VPS34 inhibitors (early inhibitors). Numerous clinical trials are underway, combining conventional chemotherapies with autophagy modulators [45]. However,

autophagy can also lead to cancer cell death, although the conditions required to transform pro-survival autophagy into a death process are not yet elucidated [44].

3. Conclusion

Over the past decade, our knowledge regarding the role of autophagy in bone tissue and bone pathology has significantly increased. Modulation of autophagy has emerged as an exciting new avenue of research for the development of new therapeutic strategies.

In postmenopausal OP, the body of preclinical work in animal models suggests that a decrease in autophagy in OB/OST participates in the development of this pathology, although definitive proof in humans remains to be established. Understanding the reason for this age-related decrease remains an important issue as these data could help identify new therapeutic molecules. In this context, an age-related increase in the expression of Rubicon, a negative regulator of autophagy, has been observed in different tissues in mice. Although the age-dependent expression level of Rubicon has not yet been studied in bone, it has already been shown that inactivation of this gene restores autophagy, thus reducing age-related phenotypes [46]. Thus, stimulating autophagy in the bone microenvironment appears to be a promising strategy for the treatment of OP. In osteopetrosis and PDB, the autophagic process is disturbed either indirectly by mutations affecting lysosomal function (osteopetrosis) or directly by mutations affecting autophagy receptors (PDB). In both cases, it is likely that autophagy perturbation contributes to the pathology by affecting osteoclastic function.

Finally, in osteosarcoma as in other tumor types, the role of autophagy is complex but tumor cells generally use this process to resist the multiple stresses to which they are subjected. In addition to blocking autophagy, identifying the molecular mechanisms that allow switching from pro-survival autophagy to cell death could lead to the identification of new treatment pathways.

In conclusion, we are at the beginning of deciphering the role of autophagy in bone tissue and bone pathology. Continued studies in this area offer the prospect of new therapeutic solutions in a wide spectrum of pathologies for which options are still sometimes limited.

Acknowledgments: The authors thank the French Society of Rheumatology (SFR) and the France Cancer association.

Declaration of interest: The authors declare that they have no ties of interest.

Références


1. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. *Nature*. 2008 Feb 28;451(7182):1069–75.
2. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. *Cell*. 2011 Nov 11;147(4):728–41.
3. Pierrefite-Carle V, Santucci-Darmanin S, Breuil V, Camuzard O, Carle GF. Autophagy in bone: Self-eating to stay in balance. *Ageing Res Rev*. 2015 Nov;24(Pt B):206–17.
4. Liu F, Fang F, Yuan H, et al. Suppression of autophagy by FIP200 deletion leads to osteopenia in mice through the inhibition of osteoblast terminal differentiation. *J Bone Miner Res Off J Am Soc Bone Miner Res*. 2013 Nov;28(11):2414–30.
5. Nollet M, Santucci-Darmanin S, Breuil V et al. Autophagy in osteoblasts is involved in mineralization and bone homeostasis. *Autophagy*. 2014 Dec 18;10(11):1965–77.
6. Zhao Y, Chen G, Zhang W et al. Autophagy regulates hypoxia-induced osteoclastogenesis through the HIF-1 α /BNIP3 signaling pathway. *J Cell Physiol*. 2012 Feb;227(2):639–48.
7. DeSelm CJ, Miller BC, Zou W et al. Autophagy proteins regulate the secretory component of osteoclastic bone resorption. *Dev Cell*. 2011 Nov 15;21(5):966–74.
8. Sánchez-Riera L, Wilson N, Kamalaraj N et al. Osteoporosis and fragility fractures. *Best Pract Res Clin Rheumatol*. 2010 Dec;24(6):793–810.
9. Almeida M, O'Brien CA. Basic biology of skeletal aging: role of stress response pathways. *J Gerontol A Biol Sci Med Sci*. 2013 Oct;68(10):1197–208.
10. Manolagas SC, Parfitt AM. WHAT OLD MEANS TO BONE. *Trends Endocrinol Metab*. 2010 Jun;21(6):369–74.
11. Gavali S, Gupta MK, Daswani B, Wani MR, Sirdeshmukh R, Khatkhatay MI. Estrogen enhances human osteoblast survival and function via promotion of autophagy. *Biochim Biophys Acta Mol Cell Res*. 2019 Sep;1866(9):1498–507.
12. Cheng L, Zhu Y, Ke D, Xie D. Oestrogen α activated autophagy has a negative effect on the anti α osteoclastogenic function of oestrogen. *Cell Prolif* [Internet]. 2020 Mar 11 [cited 2020 Oct 12];53(4). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162800/>
13. Pan F, Liu X-G, Guo Y-F et al. The regulation-of-autophagy pathway may influence Chinese stature variation: evidence from elder adults. *J Hum Genet*. 2010 Jul;55(7):441–7.
14. Zhang L, Guo Y-F, Liu Y-Z et al. Pathway-based genome-wide association analysis identified the importance of regulation-of-autophagy pathway for ultradistal radius BMD. *J Bone Miner Res Off J Am Soc Bone Miner Res*. 2010 Jul;25(7):1572–80.
15. Chen K, Yang Y-H, Jiang S-D, Jiang L-S. Decreased activity of osteocyte autophagy with aging may contribute to the bone loss in senile population. *Histochem Cell Biol*. 2014 Sep;142(3):285–95.
16. Camuzard O, Santucci-Darmanin S, Breuil V et al. Sex-specific autophagy modulation in osteoblastic lineage: a critical function to counteract bone loss in female. *Oncotarget*. 2016 Oct 11;7(41):66416–28.
17. Yang Y, Zheng X, Li B, Jiang S, Jiang L. Increased activity of osteocyte autophagy in ovariectomized rats and its correlation with oxidative stress status and bone loss. *Biochem Biophys Res Commun*. 2014 Aug 15;451(1):86–92.
18. Luo D, Ren H, Li T, Lian K, Lin D. Rapamycin reduces severity of senile osteoporosis by activating osteocyte autophagy. *Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA*. 2016 Mar;27(3):1093–101.
19. Yuan Y, Fang Y, Zhu L et al. Deterioration of hematopoietic autophagy is linked to osteoporosis. *Aging Cell*. 2020;19(5):e13114.
20. Kneissel M, Luong-Nguyen N-H, Baptist M et al. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. *Bone*. 2004 Nov;35(5):1144–56.
21. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. *Endocrinology*. 2006 Dec;147(12):5592–9.
22. Kim H-J, Zhao H, Kitaura H et al. Glucocorticoids suppress bone formation via the osteoclast. *J Clin Invest*. 2006 Aug;116(8):2152–60.
23. Lin N-Y, Chen C-W, Kagwiria R et al. Inactivation of autophagy ameliorates glucocorticoid-induced and ovariectomy-induced bone loss. *Ann Rheum Dis*. 2016;75(6):1203–10.
24. Fu L, Wu W, Sun X, Zhang P. Glucocorticoids Enhanced Osteoclast Autophagy Through the PI3K/Akt/mTOR Signaling Pathway. *Calcif Tissue Int*. 2020 Jul;107(1):60–71.

25. Shadur B, Zaidman I, NaserEddin A et al. Successful hematopoietic stem cell transplantation for osteopetrosis using reduced intensity conditioning. *Pediatr Blood Cancer*. 2018;65(6):e27010.
26. Frattini A, Orchard PJ, Sobacchi C et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. *Nat Genet*. 2000 Jul;25(3):343–6.
27. Sobacchi C, Frattini A, Orchard P et al. The mutational spectrum of human malignant autosomal recessive osteopetrosis. *Hum Mol Genet*. 2001 Aug 15;10(17):1767–73.
28. Ochotny N, Voronov I, Owen C, Aubin JE, Manolson MF. The R740S mutation in the V-ATPase $\alpha 3$ subunit results in osteoclast apoptosis and defective early-stage autophagy. *J Cell Biochem*. 2013 Dec;114(12):2823–33.
29. Héraud C, Griffiths A, Pandruvada SNM, Kilimann MW, Pata M, Vacher J. Severe Neurodegeneration with Impaired Autophagy Mechanism Triggered by Ostm1 Deficiency. *J Biol Chem*. 2014 May 16;289(20):13912–25.
30. Wartosch L, Fuhrmann JC, Schweizer M, Stauber T, Jentsch TJ. Lysosomal degradation of endocytosed proteins depends on the chloride transport protein CIC-7. *FASEB J*. 2009;23(12):4056–68.
31. van Wesenbeeck L, Odgren PR, Mackay CA, Van Hul W. Localization of the gene causing the osteopetrotic phenotype in the incisors absent (ia) rat on chromosome 10q32.1. *J Bone Miner Res Off J Am Soc Bone Miner Res*. 2004 Feb;19(2):183–9.
32. Bo T, Yan F, Guo J et al. Characterization of a Relatively Malignant Form of Osteopetrosis Caused by a Novel Mutation in the PLEKHM1 Gene. *J Bone Miner Res Off J Am Soc Bone Miner Res*. 2016;31(11):1979–87.
33. Tabata K, Matsunaga K, Sakane A, Sasaki T, Noda T, Yoshimori T. Rubicon and PLEKHM1 negatively regulate the endocytic/autophagic pathway via a novel Rab7-binding domain. *Mol Biol Cell*. 2010 Dec;21(23):4162–72.
34. McEwan DG, Popovic D, Gubas A et al. PLEKHM1 regulates autophagosome-lysosome fusion through HOPS complex and LC3/GABARAP proteins. *Mol Cell*. 2015 Jan 8;57(1):39–54.
35. Reddy SV, Menaa C, Singer FR, Demulder A, Roodman GD. Cell biology of Paget's disease. *J Bone Miner Res Off J Am Soc Bone Miner Res*. 1999 Oct;14 Suppl 2:3–8.
36. Helfrich MH, Hocking LJ. Genetics and aetiology of Pagetic disorders of bone. *Arch Biochem Biophys*. 2008 May 15;473(2):172–82.
37. Alonso N, Calero-Paniagua I, del Pino-Montes J. Clinical and Genetic Advances in Paget's Disease of Bone: a Review. *Clin Rev Bone Miner Metab*. 2017;15(1):37–48.
38. Daroszewska A, van 't Hof RJ, Rojas JA et al. A point mutation in the ubiquitin-associated domain of SQSMT1 is sufficient to cause a Paget's disease-like disorder in mice. *Hum Mol Genet*. 2011 Jul 15;20(14):2734–44.
39. McManus S, Bisson M, Chamberland R, Roy M, Nazari S, Roux S. Autophagy and 3-Phosphoinositide-Dependent Kinase 1 (PDK1)-Related Kinome in Pagetic Osteoclasts. *J Bone Miner Res Off J Am Soc Bone Miner Res*. 2016;31(7):1334–43.
40. Usategui-Martín R, Gestoso-Uzal N, Calero-Paniagua I, De Pereda JM, del Pino-Montes J, González-Sarmiento R. A mutation in p62 protein (p. R321C), associated to Paget's disease of bone, causes a blockade of autophagy and an activation of NF- κ B pathway. *Bone*. 2020 Apr;133:115265.
41. Usategui-Martín R, García-Aparicio J, Corral-Gudino L, Calero-Paniagua I, Del Pino-Montes J, González Sarmiento R. Polymorphisms in Autophagy Genes Are Associated with Paget Disease of Bone. *PLoS ONE* [Internet]. 2015 Jun 1 [cited 2020 Mar 30];10(6). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452234/>
42. Albagha OME, Visconti MR, Alonso N et al. Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone. *Nat Genet*. 2010 Jun;42(6):520–4.
43. Itoh T, Kanno E, Uemura T, Waguri S, Fukuda M. OATL1, a novel autophagosome-resident Rab33B-GAP, regulates autophagosomal maturation. *J Cell Biol*. 2011 Mar 7;192(5):839–53.
44. Camuzard O, Santucci-Darmanin S, Carle GF, Pierrefite-Carle V. Role of autophagy in osteosarcoma. *J Bone Oncol* [Internet]. 2019 Apr 3 [cited 2020 Jan 28];16. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460301/>
45. Niu J, Yan T, Guo W, Wang W, Zhao Z. Insight Into the Role of Autophagy in Osteosarcoma and Its Therapeutic Implication. *Front Oncol* [Internet]. 2019 Nov 15 [cited 2020 Oct 13];9. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873391/>
46. Nakamura S, Oba M, Suzuki M et al. Suppression of autophagic activity by Rubicon is a

signature of aging. Nat Commun. 2019 19;10(1):847.


Figure 1: Autophagy mechanism. The mechanism of autophagy and the main molecular complexes involved are presented. In response to cellular stress, mTOR is inactivated. Autophagy is then triggered by the action of the ULK1 complex and the PI3K class III complex. A double membrane called phagophore is formed in the cytosol, and encloses damaged organelles, aggregates and proteins. The phagophore then closes, leading to the formation of an autophagosome. During this process, a cytosolic protein named LC3-I is lipidated and inserted into the double membrane as LC3-II. The p62 protein acts as a receptor for autophagy by binding the ubiquitinated proteins on the one hand and the LC3-II protein on the other. Finally, the autophagosome fuses with the lysosome to degrade, thanks to the action of V-ATPase, the contents which will be recycled. PE : Phosphatidylethanolamine.

Figure 2 : Autophagy in bone pathologies. (A) Development of osteoporosis is associated with decreased autophagy with age in OB, OST, and hematopoietic stem cells (HSCs). (B) Mutations identified in osteopetrosis (OMI) induce an autophagy defect or an autophagic flux disturbance in OC, resulting in decreased resorption. (C) In Paget's disease of bone, mutations in p62, or OPTN could promote inhibition of autophagic flux and the appearance of inclusion bodies. This autophagy defect could be involved in the development of PDB, especially through the role of autophagy and ATG proteins in the differentiation and function of OC. VS: vessels.



A

Osteoporosis



B

Osteopetrosis

Mutations *TCIRG1*,
CLC7, *OSTM1*

Defective autophagy /
Flux perturbation




Inefficient OC
↓ Resorption

C

Paget's disease of bone


p62 mutations
Flux inhibition



Overactive OC
↑ Resorption

A

Osteoporosis



B

Osteopetrosis

Mutations *TCIRG1*,
CLC7, *OSTM1*

Defective autophagy /
Flux perturbation



C

Paget's disease of bone

p62 mutations
Flux inhibition

